Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: October 2011

iBio, Inc. (IBIO) Receives U.S. Patent for iBioLaunch Platform that Causes Non-transgenic Plants to Rapidly Produce Proteins

iBio, Inc., a leader in the plant-made pharmaceutical field, today announced that the U.S. Patent and Trademark Office has issued a patent that covers the viral vectors comprising the iBioLaunch™ platform. iBio owns this proprietary technology that was developed by … Continue reading

Posted in Small Cap News | Leave a comment

BluePhoenix Solutions (BPHX) Signs $17 Million Dollar Agreement to Sell AppBuilder Business

Today, BluePhoenix Solutions announced the execution of a definitive agreement to sell its AppBuilder business to Magic Software Enterprise Ltd (NASDAQ: MGIC) for $17 million. Magic Software provides mobile and cloud-enabled application and business integration platforms to businesses across the … Continue reading

Posted in Small Cap News | Leave a comment

Ventrus Biosciences Inc. (VTUS) is “One to Watch”

Ventrus Biosciences Inc., a NY-based pharmaceutical developer, while still development stage, has assembled a strong portfolio of product candidates targeting the late-stage prescription market, specifically in the gastrointestinal disorder area. A massive, underserved market of some 12.5M people in the … Continue reading

Posted in Ones to Watch | Leave a comment

Uranium Energy Corp (UEC) Acquiring Major Additional Section of Coronel Oviedo Uranium District in Paraguay

Uranium Energy is pleased to announce that, effective on October 25, 2011, the Company has entered into a Property Purchase Agreement (the “Purchase Agreement”) with three Paraguayan companies (collectively, the “Vendors”) pursuant to which the Company’s Paraguayan subsidiary proposes to … Continue reading

Posted in Uranium Energy Corp. UEC | Leave a comment

Threshold Pharmaceuticals (THLD) Data demonstrates Candidate Potential

Threshold Pharmaceuticals Inc., a biotech company focused on building a pipeline of drugs superior to conventional anticancer drugs, recently announced its ongoing phase III clinical trial results for its clinical stage hypoxia-activated prodrug, TH-302, which were presented at the Connective … Continue reading

Posted in Small Cap News | Leave a comment

Wizzard Media (WZE) Announces Invite-Only Test of Beta Version of OnPublish Program on Libsyn.com for Podcast Playback with Facebook and Twitter

Wizzard Media, the world’s largest podcast network, today announced that is has begun a private beta version test of its OnPublish program which will integrate support for both Facebook and Twitter in the libsyn.com publishing platform.  With the OnPublish program, … Continue reading

Posted in Small Cap News | Leave a comment

Lake Shore Gold Corp. (LSG) Announces Results for Its Wholly Owned Fenn-Gibb Project

Lake Shore Gold Corp. (LSG), a Company that engages in the acquisition, exploration, and development of gold properties in northern Ontario and Quebec of Canada, as well as in Mexico, has reported the results of 4 holes, 3 of which … Continue reading

Posted in Small Cap News | Leave a comment

USA Technologies, Inc. (USAT) Ends Fiscal First Quarter with $42 Million in Small Ticket Transactions; Dollar Volume Up 75% from Last Year

USA Technologies, Inc., a leader of wireless, cashless payment and M2M telemetry solutions for self-serve, small ticket retailing industries, today announced positive earnings for the first fiscal quarter which reflected a record 25 million small ticket transactions earning $42 million. … Continue reading

Posted in Small Cap News | Leave a comment

SciClone Pharmaceuticals (SCLN) Continues Growth in China

SciClone Pharmaceuticals is a China-centric specialty pharmaceutical company focused on therapies for oncology and infectious diseases, along with cardiovascular, urological, respiratory, and central nervous system disorders. The company was founded in 1989 and is headquartered south of San Francisco in … Continue reading

Posted in Small Cap News | Leave a comment

Dynavax Technologies Corp. (DVAX) HEPLISAV Demonstrates Statistical Significance and Superiority

Dynavax Technologies Corp., a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases, today announced that it has unblinded its phase 3 primary endpoint immunogenicity data in subjects with chronic kidney disease. … Continue reading

Posted in Small Cap News | Leave a comment